Edwards Lifesciences Corporation
EW
$83.39
$0.951.15%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -67.11% | 181.58% | 195.71% | 197.68% | 190.65% |
| Total Depreciation and Amortization | 4.82% | 0.07% | 3.44% | 7.11% | 3.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 101.58% | -6,697.23% | -2,957.32% | -2,718.05% | -2,439.67% |
| Change in Net Operating Assets | -4,475.61% | 89.85% | 107.99% | 50.73% | 96.89% |
| Cash from Operations | 26.09% | -8.22% | 65.88% | -39.46% | -22.61% |
| Capital Expenditure | 26.92% | 29.66% | 5.33% | 0.24% | -24.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 58.44% | -2,408.26% | -2,408.26% | -1,015.34% | -408.22% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -114.84% | 513.20% | 713.95% | 594.85% | 521.77% |
| Cash from Investing | -137.58% | 600.41% | 887.77% | 1,230.78% | 1,041.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 16.73% | 16.94% | -11.99% | 5.65% | 12.12% |
| Repurchase of Common Stock | 40.48% | -54.87% | -116.94% | -20.44% | -16.23% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -131.52% | -2,696.72% | -4,343.48% | -7,830.77% | -3,273.33% |
| Cash from Financing | 35.65% | -95.03% | -194.26% | -38.26% | -25.40% |
| Foreign Exchange rate Adjustments | 117.09% | -206.46% | -63.52% | 129.76% | -890.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -143.56% | 167.26% | 444.47% | 409.00% | 1,299.20% |